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Dear Sirs,
Riluzole is the only globally licensed drug treatment for 
amyotrophic lateral sclerosis (ALS), a rapidly progressive 
neurodegenerative condition. Trials and population studies 
have reported a survival gain of approximately 2–4 months 
with treatment [1, 2], and a low frequency of adverse effects 
[3]. The National Institute for Health and Care Excellence 
(NICE) recommends that clinicians offer riluzole to all peo-
ple with ALS (pwALS) in the absence of contraindications 
[4]. However, in practice, prescribing and uptake are likely 
to be influenced by a number of clinical factors. Current 
evidence on rate of treatment discontinuation is limited by 
selection bias, stemming mainly from trials and small obser-
vational studies.
We investigated factors influencing riluzole prescription, 
uptake and discontinuation using data from a large national 
disease register with 99% case ascertainment.
Participants were drawn from the Clinical Audit Research 
and Evaluation of MND (CARE-MND) platform, a prospec-
tively maintained population-based register comprising 
longitudinal clinical, and research data for all pwALS in 
Scotland [5]. We extracted clinical characteristics of people 
with definite, probable or possible ALS [6]. Summary sta-
tistics are reported as median with interquartile range (IQR). 
Data were analysed using multivariable multinomial logistic 
regression and are reported as odds ratio (OR) with 95% 
confidence intervals (CIs). Missing data were handled using 
multiple imputation (m = 5). Data on the presence/absence 
of cognitive impairment were used to inform imputation 
of missing Edinburgh Cognitive and Behavioural Screen 
(ECAS) scores. Analyses were performed in R (3.6.2.).
768 pwALS were identified between January 2015 and 
April 2020. 468 pwALS (60.9%) were male, median age at 
diagnosis was 68 years (IQR 60–75) and median time from 
onset to diagnosis was 11 months (IQR 7–19). Site of onset 
was limb (338, 63.3%), bulbar (150, 28.1%), mixed (38, 
7.1%) and pure respiratory (8, 1.5%). The median ALSFRS-
R score was 38 (IQR 31–42) and the median ECAS score 
was 109/136 (IQR 91–115, n = 253).
Of all pwALS, 632 (86.5%) were offered riluzole and 
283 (38.7%) did not commence treatment, which was due to 
patient preference in 223 (78.8%) cases (Fig. 1). Older age 
was significantly associated with pwALS not being offered 
riluzole, and with not starting riluzole. Sex, diagnostic delay, 
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ALSFRS-R total and swallow subscores, and ECAS scores 
were not associated with prescription or uptake of riluzole 
(Table 1).
Of those who started riluzole, 54 (15.4%) subsequently 
discontinued treatment. The most common reasons for dis-
continuation were gastrointestinal adverse effects (24.8%), 
including nausea, abdominal discomfort, constipation, and 
anorexia. Other adverse effects (including fatigue/malaise) 
accounted for 13.0%, deranged liver function 11.1%, and 
allergic reactions 9.3%. 13% discontinued due to ongoing 
ALS progression. In the remainder, the reason was unclear. 
Median time until discontinuation was 3 months for adverse 
effects and ALS progression (IQR 1.8–3.3 and 2.0–5.0, 
respectively) and 4.5 months for deranged liver function 
tests (IQR 2.5–6.0).
The proportion of pwALS in Scotland offered riluzole 
(86.5%) is in keeping with previous estimates of 66–100% 
in the United Kingdom [7, 8] and 57–85% internationally 
[9, 10].
Older age was associated with lower rates of riluzole pre-
scription and uptake, which may be because of prescribers’ 
and/or pwALS’ concerns about increased vulnerability to 
Fig. 1  Patient flow chart
Table 1  Factors associated with being offered riluzole and not starting riluzole, compared to starting riluzole (reference category)
ALSFRS-R Amyotrophic lateral sclerosis functional rating scale, CI confidence interval, ECAS Edinburgh Cognitive and Behavioural Screen, OR 
odds ratio
Characteristic Not offered riluzole (n = 99) OR 
(95% CIs); p value
Offered but not started riluzole 
(n = 283) OR (95% CIs)
Started riluzole 
(n = 349) (Reference 
category)
Age at clinical ALS diagnosis (years) 1.05 (1.03, 1.08); p < 0.001 1.03 (1.01, 1.04); p < 0.001 1
Male sex 1.05 (0.65, 1.69); p = 0.86 1.07 (0.76, 1.51); p = 0.69 1
Time between symptom onset and clinical 
ALS diagnosis (months)
1.01 (1.00, 1.02); p = 0.14 1.00 (0.99, 1.01); p = 0.61 1
Total ALSFRS-R score (0–4) 0.97 (0.94, 1.01); p = 0.12 0.99 (0.96, 1.01); p = 0.36 1
ALSFRS swallow subscore (0–48) 0.77 (0.55, 1.06); p = 0.11 0.87 (0.69, 1.10); p = 0.24 1
ECAS total score (0–136) 0.99 (0.97, 1.01); p = 0.21 0.99 (0.98, 1.00); p = 0.08 1
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adverse effects owing to comorbidity and polypharmacy. 
Additionally, therapeutic nihilism regarding the modest 
survival gain conferred by riluzole may be more prominent 
in this group; however, recent research found that the sur-
vival benefit of riluzole is greater in older pwALS [11]. This 
study, together with our data, emphasises the importance of 
offering Riluzole to all pwALS.
15% of pwMND discontinued riluzole; this figure var-
ied between 4–40% in previous research [3]. Our data offer 
insight into reasons for discontinuation, which may inform 
pre-treatment discussion with pwALS.
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